Cargando…
First Successful Lung Transplantation for Pulmonary Fibrosis Due to Severe COVID-19 Infection in the US
INTRODUCTION: Lung transplantation can potentially be a life-saving treatment for patients with non-resolving COVID-19 acute respiratory distress syndrome. Concerns limiting transplant include recurrence of SARS-CoV-2 infection in the allograft, technical challenges imposed by viral-mediated injury...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979372/ http://dx.doi.org/10.1016/j.healun.2021.01.2033 |
_version_ | 1783667270059294720 |
---|---|
author | Kurihara, C. Bharat, A. |
author_facet | Kurihara, C. Bharat, A. |
author_sort | Kurihara, C. |
collection | PubMed |
description | INTRODUCTION: Lung transplantation can potentially be a life-saving treatment for patients with non-resolving COVID-19 acute respiratory distress syndrome. Concerns limiting transplant include recurrence of SARS-CoV-2 infection in the allograft, technical challenges imposed by viral-mediated injury to the native lung. Here, we report the first successful lung transplantation in a patient with non-resolving COVID-19 associated acute respiratory distress syndrome in the United States. CASE REPORT: The recipient was a 28-year old female with past medical history of neuromyelitis optica treated with mycophenolate and rituximab who developed COVID pneumonia leading acute respiratory distress syndrome. The patient was intubated for 8 days with prone prior to initiation of VV ECMO. Her ECMO course was complicated by right sided pneumothorax requiring multiple pleural tubes and the development of Serratia marcescens pneumonia with left lower lung necrosis, and a liver capsular bleed necessitating emergent exploratory laparotomy. (Figure1a, b) She received antibiotics, remdesivir, hydroxychloroquine, tocilizumab, and convalescent plasma. However there was no signs of recovery and she was listed for lung transplantation after ECMO support for 32 days . Implantation was supported with central VA ECMO, and there was severe dense vascular adhesions bilaterally with severe distortion of hilar. (Figure1c) Explanted Lungs damaged by COVID-19 were free of virus but pathology showed extensive evidence of acute interstitial inflammation with fibrosis which consistence with end-stage pulmonary fibrosis. (Figure1d, e) The patient was decannulated from VV ECMO on POD 17, and was discharged on POD 27. (Figure1f) Four months after transplantation, she is at home with oxygen saturations above 98% on room air. SUMMARY: Our experience suggest that lung transplant is the only option for survival for some patients with severe COVID-19 develop fibrotic lung. |
format | Online Article Text |
id | pubmed-7979372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79793722021-03-23 First Successful Lung Transplantation for Pulmonary Fibrosis Due to Severe COVID-19 Infection in the US Kurihara, C. Bharat, A. J Heart Lung Transplant (1265) INTRODUCTION: Lung transplantation can potentially be a life-saving treatment for patients with non-resolving COVID-19 acute respiratory distress syndrome. Concerns limiting transplant include recurrence of SARS-CoV-2 infection in the allograft, technical challenges imposed by viral-mediated injury to the native lung. Here, we report the first successful lung transplantation in a patient with non-resolving COVID-19 associated acute respiratory distress syndrome in the United States. CASE REPORT: The recipient was a 28-year old female with past medical history of neuromyelitis optica treated with mycophenolate and rituximab who developed COVID pneumonia leading acute respiratory distress syndrome. The patient was intubated for 8 days with prone prior to initiation of VV ECMO. Her ECMO course was complicated by right sided pneumothorax requiring multiple pleural tubes and the development of Serratia marcescens pneumonia with left lower lung necrosis, and a liver capsular bleed necessitating emergent exploratory laparotomy. (Figure1a, b) She received antibiotics, remdesivir, hydroxychloroquine, tocilizumab, and convalescent plasma. However there was no signs of recovery and she was listed for lung transplantation after ECMO support for 32 days . Implantation was supported with central VA ECMO, and there was severe dense vascular adhesions bilaterally with severe distortion of hilar. (Figure1c) Explanted Lungs damaged by COVID-19 were free of virus but pathology showed extensive evidence of acute interstitial inflammation with fibrosis which consistence with end-stage pulmonary fibrosis. (Figure1d, e) The patient was decannulated from VV ECMO on POD 17, and was discharged on POD 27. (Figure1f) Four months after transplantation, she is at home with oxygen saturations above 98% on room air. SUMMARY: Our experience suggest that lung transplant is the only option for survival for some patients with severe COVID-19 develop fibrotic lung. Published by Elsevier Inc. 2021-04 2021-03-20 /pmc/articles/PMC7979372/ http://dx.doi.org/10.1016/j.healun.2021.01.2033 Text en Copyright © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | (1265) Kurihara, C. Bharat, A. First Successful Lung Transplantation for Pulmonary Fibrosis Due to Severe COVID-19 Infection in the US |
title | First Successful Lung Transplantation for Pulmonary Fibrosis Due to Severe COVID-19 Infection in the US |
title_full | First Successful Lung Transplantation for Pulmonary Fibrosis Due to Severe COVID-19 Infection in the US |
title_fullStr | First Successful Lung Transplantation for Pulmonary Fibrosis Due to Severe COVID-19 Infection in the US |
title_full_unstemmed | First Successful Lung Transplantation for Pulmonary Fibrosis Due to Severe COVID-19 Infection in the US |
title_short | First Successful Lung Transplantation for Pulmonary Fibrosis Due to Severe COVID-19 Infection in the US |
title_sort | first successful lung transplantation for pulmonary fibrosis due to severe covid-19 infection in the us |
topic | (1265) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979372/ http://dx.doi.org/10.1016/j.healun.2021.01.2033 |
work_keys_str_mv | AT kuriharac firstsuccessfullungtransplantationforpulmonaryfibrosisduetoseverecovid19infectionintheus AT bharata firstsuccessfullungtransplantationforpulmonaryfibrosisduetoseverecovid19infectionintheus |